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Common variants in MMP20 at 11q22.2 predispose
to 11q deletion and neuroblastoma risk
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John M. Maris2,4 & Hakon Hakonarson1,4,5
MYCN amplification and 11q deletion are two inversely correlated prognostic factors of poor
outcome in neuroblastoma. Here we identify common variants at 11q22.2 within MMP20 that
associate with neuroblastoma cases harboring 11q deletion (rs10895322), using GWAS in 113
European-American cases and 5109 ancestry-matched controls. The association is replicated
in 44 independent cases and 1902 controls. Our study yields novel insights into the genetic
underpinnings of neuroblastoma, demonstrating that the inherited common variants reported
contribute to the origin of intra-tumor genetic heterogeneity in neuroblastoma.
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Neuroblastoma, a malignant tumor of the developingsympathetic nervous system, remains among the mostlethal and difficult to cure cancers that affect children1.
Our previous GWA studies have revealed that common SNPs
within or near CASC15, BARD1, LMO1, HSD17B12, HACE1, and
LIN28B are associated with susceptibility to develop neuro-
blastoma2–6. The majority of neuroblastomas behave in highly
malignant fashion, with widespread metastatic dissemination
typical at the time of diagnosis. These “high-risk” neuroblastoma
are characterized by genomic instability resulting in segmental
chromosomal alterations and high-level amplification of the
MYCN gene locus. These are prognostically relevant, with MYCN
amplification (MNA), 11q deletion and 1p deletion currently used
as biomarkers to assign therapy, but the mechanisms by
which these chromosomal rearrangements arise remain obscure.
MNA and 11q deletion have been shown to be almost mutually
exclusive7, implying two distinct subtypes underlying high-risk
neuroblastoma. As the genetic contribution to neuroblastoma
susceptibility is highly heterogeneous and complex, additional
loci may be associated with a specific type of chromosomal
abnormality in neuroblastoma.
Here we conducted GWASs for three subtypes of
neuroblastoma, including MNA, 11q-deletion and 1p-deletion
neuroblastoma. We identify a susceptibility locus in MMP20
for 11q-deletion neuroblastoma and subsequently replicate
interesting markers in an independent cohort. Our study provides
new insights into the genetic architecture of neuroblastoma
subtypes and suggests directions for subset-specific therapeutic
strategies.
Results
Identification of prognostic biomarkers. To profile genomic
alterations of neuroblastoma, we genotyped 641 neuroblastoma
tumor DNA samples, using Illumina HumanHap550 or 610 SNP
arrays including 442 samples with matched blood DNA samples
(Supplementary Data 1). Tumor-based copy number segments
were first calculated by ASCAT and OncoSNP, and then curated
manually. Tumor samples were excluded if the copy number
results were suggestive of noise or if no amplification/deletion
events were detected. Following thorough quality control, 437
tumor samples were kept for analysis, including 300 with
matched blood DNA genotyping data. A total of 154
neuroblastoma tumors were identified with MNA, 245 with
11q deletion, and 167 with 1p deletion, respectively. The inverse
correlation between MNA and 11q deletion events was also
confirmed (Pearson correlation coefficient = −0.83), only 27
neuroblastoma tumors were identified with both MNA and
11q deletion. Besides the commonly observed MNA, 11q deletion
and 1q deletion variations in neuroblastoma (Supplementary
Fig. 1), we also identified a number of genomic regions targeted
by low frequency somatic aberrations (Supplementary Figs. 2–7
and Supplementary Tables 1 and 2). In this regard,
focal amplifications of ALK, CCND1, LIN28B, MDM2, and
19q13.42 observed in our study have been previously
implicated in individual neuroblastoma studies (Supplementary
Figs. 2 and 4)8–12. However, to our knowledge, recurrent focal
amplifications of MYC, ZFHX3, KRAS, RRAS2, and CYTH1 have
not been reported in neuroblastoma primary tumors before
(Supplementary Note 1 and Supplementary Fig. 3). Interestingly,
we observed a number of cases (56/628) with low-level
amplification of CCND1 (8.9%). In most of those cases,
the amplification of CCND1 co-occurred with 11q deletion
(53/56, 94.6%), suggesting these two events are highly correlated
(Supplementary Note 1).
Discovery stage. We subsequently identified 113 11q-deletion
cases of European-American ancestry with available blood
DNA genotyping data, and we performed GWAS in this subset
together with 5109 ancestry-matched controls (Supplementary
Fig. 8). The genomic inflation factor was 1.0 (Supplementary
Fig. 9). Three SNPs within MMP20 at 11q22.2 (rs10895322, P
= 2.62 × 10−9, OR = 2.858; rs3781788, P = 2.46 × 10−8, OR =
2.505; rs2280211, P = 3.11 × 10−9, OR = 2.604, logistic regres-
sion test) were found to surpass the conventional genome-wide
significance threshold (P = 5 × 10−8, logistic regression test,
Table 1 and Supplementary Fig. 10). All three SNPs map to
the intronic regions of MMP20 and showed a high degree of
linkage disequilibrium (Supplementary Fig. 11). Considering
that three case subgroups were investigated in this study,
we used an adjusted threshold by dividing the conventional
threshold by three (P = 1.7 × 10−8, logistic regression test)
with the top SNP rs10895322 remaining significant.
The reported SNPs at previously identified neuroblastoma
susceptibility loci, including 2q35 (BARD1), 6p22.3 (CASC15),
and 11p15.4 (LMO1) were also nominally associated with
11q deletion (Supplementary Table 3). As the 11q22.2 region
harboring MMP20 is commonly deleted in 11q-deletion
neuroblastomas, we investigated 11q-deletion cases that are
heterozygous (G/A) for rs10895322 and found that the risk
allele (G) is preferentially retained in tumors (P = 2.09 × 10−3,
binomial test). This result is consistent with the observation
of preferential allelic imbalance in other cancers (Supple-
mentary Fig. 12)13, 14. We did not observe evidence for epistasis
between the previously reported loci and the newly discovered
Table 1 Association results for the top three genotyped SNPs at 11q22.2
SNP Study A1/A2 Freq1 Freq2 OR 95% CI P value
rs10895322 Discovery G/A 0.164 0.064 2.858 1.991–4.101 2.62 × 10−9
Replication G/A 0.131 0.057 2.478 1.296–4.740 4.58 × 10−3
Combined 2.763 2.015–3.789 2.89 × 10−10
rs3781788 Discovery T/C 0.201 0.091 2.505 1.794–3.497 2.46 × 10−8
Replication T/C 0.148 0.087 1.813 0.995–3.301 0.0486
Combined 2.321 1.733–3.106 1.58 × 10−8
rs2280211 Discovery C/T 0.208 0.092 2.604 1.875–3.615 3.11 × 10−9
Replication C/T 0.148 0.088 1.795 0.986–3.269 0.0525
Combined 2.390 1.792–3.187 3.16 × 10−9
A1/A2: risk allele/protective allele
Freq1: case frequency
Freq2: control frequency
P: P value calculated by logistic regression test
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00408-8
2 NATURE COMMUNICATIONS | 8:  569 |DOI: 10.1038/s41467-017-00408-8 |www.nature.com/naturecommunications
MMP20 locus (Supplementary Tables 4 and 5), suggesting that
these susceptibility loci contributed to disease risk,
independently.
We also performed SNP association analysis in cases with
MNA and 1p-deletion, respectively. The previously reported
loci on 2q35 (BARD1) and 6p22.3 (CASC15)2, 3, reached
genome-wide significance (Supplementary Fig. 3 and
Supplementary Table 3) in the GWAS of 260 MNA cases
(Methods) and 5109 controls and the 6p22.3 locus also showed
a P value near genome-wide significance in the GWAS of 69
1p-deletion cases and 5109 controls. However, no significant
associations at 11q22.2 was detected in either MNA or
1p-deletion neuroblastoma (Supplementary Table 3). When
GWAS was performed in the 113 11q-deletion cases and 282
controls (78 undeleted 11q and 204 MNA neuroblastomas,
Methods) of European-American ancestry, the 11q22.2 locus
was still nominally significant (rs10895322, P= 5.50 × 10−5,
OR= 2.811, logistic regression test, Supplementary Table 6),
indicating a unique and independent role of the 11q22.2 locus
in the 11q deletion cases. We subsequently applied the
subset-based approach ASSET to investigate the impact of the
11q22.2 (MMP20), 2q35 (BARD1), 6p22.3 (CASC15), and
11p15.4 (LMO1) loci on the subtypes. ASSET is designed for a
single case–control study in which cases are treated as
distinct disease subtypes15. This permits both case–control and
case–case comparisons (among subsets of disease subtypes) for
the detection of the strongest association signals. Here, 11q
deletion and MNA subtypes were included for the
ASSET analysis, as they are negatively correlated and represent
two distinct subtypes of neuroblastoma. However, 1p deletion
was excluded as an independent subtype, since 1p deletion
often co-occurs with 11q deletion or MNA. The ASSET results
confirm the association between 11q22.2 and 11q-deletion
subtype (Table 2).
Table 2 Results from subtype analysis of neuroblastoma risk loci
SNP Overall logistic Subset search (case–control) Subset search (case-complement)
P value OR (95% CI) P value OR (95% CI) Best Subset P value OR (95% CI) Best Subset
11q22.2 MMP20
rs10895322 2.55E-03 1.5 (1.153–1.952) 2.98E-08 2.828 (1.958–4.084) 11q-del 2.85E-08 2.83 (1.96–4.087) 11q-del
rs3781788 1.46E-04 1.549 (1.236–1.942) 8.27E-09 2.682 (1.918–3.752) 11q-del 9.88E-09 2.671 (1.909–3.738) 11q-del
rs2280211 4.54E-04 1.506 (1.198–1.893) 9.77E-09 2.673 (1.91–3.74) 11q-del 1.05E-08 2.667 (1.906–3.732) 11q-del
2q35 BARD1
rs3768716 1.39E-12 1.795 (1.527–2.11) 1.22E-12 1.986 (1.643–2.399) 11q-del,MNA 2.09E-12 1.795 (1.525–2.113) 11q-del,MNA
rs17487792 1.10E-12 1.799 (1.53–2.114) 7.58E-13 1.992 (1.65–2.406) 11q-del,MNA 1.61E-12 1.966 (1.63–2.372) 11q-del,MNA
rs7587476 1.84E-12 1.769 (1.51–2.074) 2.18E-12 1.949 (1.618–2.348) 11q-del,MNA 2.87E-12 1.769 (1.507–2.076) 11q-del,MNA
6p22.3 CASC15
rs4712653 2.12E-11 1.719 (1.467–2.015) 7.42E-11 1.719 (1.461–2.024) 11q-del,MNA 7.45E-11 1.719 (1.461–2.024) 11q-del,MNA
rs9295536 5.07E-11 1.691 (1.446–1.979) 9.90E-11 1.691 (1.442–1.984) 11q-del,MNA 9.94E-11 1.691 (1.442–1.984) 11q-del,MNA
rs6939340 5.58E-11 1.698 (1.45–1.99) 1.36E-10 1.698 (1.445–1.996) 11q-del,MNA 1.37E-10 1.698 (1.445–1.996) 11q-del,MNA
11p15.4 LMO1
rs110419 2.28E-03 1.27 (1.089–1.481) 2.44E-03 1.605 (1.182–2.179) 11q-del 2.93E-03 1.593 (1.172–2.166) 11q-del
Association results are reported from the analysis of the newly discoveredMMP20 locus, and three previously reported loci including BARD1, CASC15, and LMO1. P values are calculated by ASSET analysis
Table 3 Imputed SNPs surpassing genome-wide significance within and near MMP20
SNP POS A1 Discovery Replication Combined
OR P value OR P value OR P value
rs11225333 102454685 A 2.838 4.34 × 10−7 2.206 0.012 2.673 9.71 × 10−10
rs5024119 102463359 G 2.861 4.35 × 10−7 2.370 0.007 2.736 4.07 × 10−10
rs10895322 102470256 A 2.854 4.64 × 10−7 2.361 0.007 2.728 4.54 × 10−10
rs3781788 102477556 C 2.616 1.92 × 10−7 1.813 0.048 2.404 2.42 × 10−9
rs7115479 102483150 C 2.617 1.88 × 10−7 1.809 0.049 2.403 2.44 × 10−9
rs7122793 102484945 G 2.559 3.60 × 10−7 1.657 0.103 2.322 2.79 × 10−8
rs7123742 102484946 C 2.629 1.40 × 10−7 1.650 0.106 2.372 9.75 × 10−9
rs7126560 102485553 G 2.636 1.53 × 10−7 1.810 0.049 2.417 1.93 × 10−9
rs17099063 102487065 C 2.610 2.02 × 10−7 1.797 0.052 2.395 2.82 × 10−9
rs2280211 102488131 A 2.604 2.14 × 10−7 1.795 0.052 2.390 3.09 × 10−9
rs11225344 102493269 G 2.625 2.04 × 10−7 1.931 0.024 2.443 2.95 × 10−9
rs2292731 102496405 C 2.425 2.08 × 10−7 1.637 0.075 2.211 1.93 × 10−8
rs12786739 102499728 T 2.417 2.09 × 10−7 1.631 0.077 2.204 2.15 × 10−8
rs12798540 102508004 G 2.866 4.59 × 10−8 1.385 0.358 2.492 1.31 × 10−8
rs12575154 102534875 C 2.792 1.81 × 10−7 1.470 0.296 2.473 3.14 × 10−8
rs34902925 102550821 A 2.796 1.93 × 10−7 1.484 0.285 2.480 2.92 × 10−8
POS: genomic position in human genome build hg19
A1: coded allele
P: P value calculated by frequentist association test
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Replication stage. To replicate our findings, we genotyped the
tumor and blood DNA samples of additional 192 neuroblastoma
cases using OMNI-Express SNP array. Copy number analysis of
the tumor samples identified 80 of them with 11q deletion,
Among the 80 11q-deleltion cases, we identified 44 cases
of European-American ancestry. The 44 cases and 1902
ancestry-matched controls were included for GWAS replication
(Supplementary Fig. 8). All of the three genome-wide significant
SNPs (rs10895322, P= 2.62 × 10−9, OR= 2.858; rs3781788, P=
2.46 × 10−8, OR= 2.505; rs2280211, P= 3.11 × 10−9, OR= 2.604,
logistic regression test) at 11q22.2 in the discovery cohort showed
the same direction of association in the replication set, and two of
them had a P value <0.05 (Table 1). The association was further
strengthened by a meta-analysis combing the discovery and
replication studies (Table 1).
Imputation analysis. To evaluate additional variants not assayed
directly on the genotyping arrays, we imputed unobserved
genotypes at 11q22.2 using 1000 Genomes Project data as the
reference. Imputation identified 13 additional SNPs that were
significantly associated with neuroblastoma (Table 3). The top
SNPs, both genotyped and imputed were all located in a strong
linkage disequilibrium region (r2> 0.8) within MMP20 (Fig. 1
and Supplementary Fig. 11).
Exome sequencing analysis. To investigate the possibility of
association being a consequence of a rare variant, we analyzed
exome sequencing data from 229 neuroblastoma samples
and whole-genome sequencing data from 143 neuroblastoma
samples from the TARGET database (https://ocg.cancer.gov/
programs/target/). We examined for the presence of low
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frequency variants (<0.01 in 1000 Genomes Database) detected in
the MMP20 coding region. Only one pathogenic variant was
detected, which is associated with amelogenesis imperfecta.
In addition, the frequency of rare variants presents in
neurobalstoma cases is not significantly different in the 1000
Genome Database, indicating that the association we report here
is unlikely a consequence of a rare variant (Supplementary
Data 2).
eQTL analysis. To gain further insight into the biological
mechanisms of the association at 11q22.2, we performed an
expression quantitative trait loci (eQTL) analysis using gene
expression data from 34 11q-deletion neuroblastoma cases. eQTL
analysis showed that rs10895322 is significantly associated with
MMP20 expression in samples with 11q deletion (P= 7.7 × 10−5,
Student’s t-test, Fig. 2). We did not observe association between
rs10895322 genotypes and the expression level of other
genes near MMP20 in the 11q-deletion samples. In addition, no
significant association was detected between rs10895322
and MMP20 expression levels in undeleted 11q neuroblastoma
samples (P= 0.94, Student’s t-test, Fig. 2).
Discussion
MMP20 belongs to Matrix metalloproteinase (MMP) gene family,
which is involved in tooth enamel formation and defects of
MMP20 have been associated with amelogenesis imperfecta16. A
recent GWAS reported association of MMP20 with neovascular
lesion size in age-related macular degeneration (AMD),
suggesting a potential role for anti-vascular endothelial
growth factors (anti-VEGFs) drugs in reversing the choroidal
neovascularization (CNV) disease process17. Interestingly, the
lead SNP identified in our GWAS of 11q-deletion neuroblastoma
(rs10895322), is also the top SNP reported in the GWAS of
neovascular lesion size in AMD17. The risk allele of rs10895322 in
our study is also the same allele that promotes neovascular lesion
size in the GWAS of AMD, implying that the risk attributed
to rs10895322 in neuroblastoma may be mediated through
comparable angiogenesis process that is regulated by MMP20.
Our eQTL analysis further indicated that rs10895322 may
regulate MMP20 expression specifically in 11q-deletion
neuroblastoma cases. Given that knockdown of MYCN
expression has been shown to significantly block VEGF secretion
in neuroblastoma cells with MNA, but not in neuroblastoma
cells without MNA, it is conceivable that distinct molecular
mechanisms of angiogenesis may underlie the MNA and
non-MNA neuroblastoma disease process18.
In summary, here we demonstrate that common variants at the
MMP20 locus are exclusively associated with the 11q-deletion
subtype of neuroblastoma, indicating that the inherited
common variants may contribute to the origin of intra-tumor
genetic heterogeneity in neuroblastoma. In addition, we have
refined our understanding of somatic chromosomal structural
rearrangements in the high-risk neuroblastoma genome. Future
studies addressing the mechanism by which MMP20 impacts
tumorigenesis of the 11q-deleted subset of neuroblastoma, which
may allow for the development of novel molecular subset-specific
therapeutic strategies.
Methods
Sample collection. The neuroblastoma cases in the study were individuals
diagnosed with neuroblastoma or ganglioneuroblastoma registered through
the Children’s Oncology Group (COG). The tumor and blood samples were
obtained through the COG Neuroblastoma bio-repository for specimen
collection at the time of diagnosis. The majority of specimens were annotated
with clinical and genomic information containing age at diagnosis, site of
origin, INSS disease stage19, International Neuroblastoma Pathology
Classification20.
Control subjects were recruited by the Center for Applied Genomics
through the Children’s Hospital of Philadelphia (CHOP) Health Care Network,
including four primary care clinics and several group practices and outpatient
practices that included wellchild visits. Eligibility criteria for control subjects
were (i) selfreporting as Caucasian and (ii) no serious underlying medical disorder,
including cancer. The Research Ethics Board of CHOP approved the study. Written
informed consent was obtained from all subjects by nursing and medical assistant
study staff under the direction of CHOP clinicians.
Calculation of somatic copy number aberrations. Copy number segments of
the tumor samples were predicted with ASCAT, which accounts for the normal
cell contamination and tumor aneuploidy21. Previous study pointed out that
the SNP genotyping arrays showed a “genomic wave patterns” issue in
which signal intensity was correlated to local guanine-cytosine content. The
genomic_wave.pl program in the PennCNV package was used to adjust the
signal intensity value22.
Genome-wide association studies of three subtypes. We identified and
report on 300 neuroblastoma samples with matched blood/tumor genotyping data.
Among them, a total of 125 1p-deletion, 171 11q-deletion, and 101 MNA cases
were identified. After population stratification, 78 1p-deletion, 113 11q-deletion,
and 56 MNA cases of European ancestry were included for the association
analysis. In addition, we genotyped the blood DNA samples of 299 MNA cases
(MYCN amplification was identified by fluorescence in situ hybridization (FISH) as
previously described23). Hybridization studies were performed with a cosmid
probe (from the MYCN genomic locus on chromosome 2) that had been
nick-translated with digoxigenin-dUTP. The labeled probe was combined with
human Cot1 DNA and allowed to hybridize overnight at 37°C to fixed tumor
cells. Specific hybridization signals were detected by incubating the hybridized
slides in a solution containing fluorescein-conjugated antidigoxigenin antibodies.
Probe detection for two-color experiments included Texas red avidin and
counterstaining with 4ʹ, 6-diamidino-2-phenylindole (DAPI). Fluorescence
microscopy was performed with a Zeiss microscope equipped with either
fluorescein filter sets or a three-color filter set for FITC, Texas red, and DAPI.
Two-color FISH was performed with a biotin-labeled chromosome 2 centromere-
specific probe. 204 of the 299 MNA cases (detected by FISH) are European
decedents. Finally, 260 MNA cases of European ancestry were included. The same
set of ancestry-matched controls (5109 individuals) was used for the 11q-deletion,
1p-deletion and MNA GWAS.
Quality control. SNPs were filtered by genotype missing rate (<0.95), minor allele
frequency (<0.01), and Hardy–Weinberg equilibrium P value (<0.00001).
Samples with a genotype call rate below 95% were excluded. To remove cryptic
relatedness between samples, the identity-by-descent (IBD) scores were calculated
and one individual in the pairs of subjects was removed with IBD>0.25. Principal
component analysis were performed by using EIGENSTRAT to detect and correct
for potential substructures and outliers24.
Statistical analysis. The association analysis were carried out in PLINK using
logistic test. The genomic inflation factors for 11q deletion, 1-p deletion and MNA
GWAS were 1. Pairwise epistasis tests between the top significant SNPs at 11q22. 2
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were also conducted with PLINK. Meta-analysis was performed by GWAMA25.
Fixed effects P values were reported.
Cases and controls were pruned to a common set of SNPs before imputation.
Genotype imputation at the 11q22.32 locus was performed with IMPUTE2 using
the reference panel 1000 Genome Phase I integrated variants set26. We used
SHAPEIT recommended by Howie et al to infer the haplotypes before
imputation27. In consideration of the uncertainty of imputation, association test of
the imputed genotypes was calculated with the SNPTEST v2 package28.
Gene expression analysis. The mRNA expression data of 100 primary tumors
and 29 cell lines were generated using Illumina Human 6 version 2 expression l
bead chip. The mRNA expression data were previously published29 and
deposited in the Gene Expression Omnibus (GSE19274) database. 62 of the 100
neuroblastoma primary tumors have matched genotyping data.
Sequencing data analysis. Paired end exome sequencing data for 229
individual germline samples was obtained from NCI TARGET database
(https://ocg.cancer.gov/programs/target/). Sample processing, exome capture and
DNA sequencing methods are described in detail by Pugh et al.30 and on the
Target website (https://ocg.cancer.gov/programs/target/target-methods#3258).
Fastq file sequences were aligned to the HG19/GRCh37 human genome
sequence reference using BWA-mem31. Generated sam files were sorted,
converted to bam format and duplicates removed using Samtools. Local
realignment and variant calling including SNPs and short indels, was done
using GATK IndelRealigner and UnifiedGenotyper respectively32.
Whole-genome calls Complete Genomics masterVarBeta files containing variant
calls for 143 neuroblastoma germline samples were obtained from the NCI
TARGET database (https://ocg.cancer.gov/programs/target/). Sixty-five of the
germline samples were also in the whole exome sequence sample set. The
effect of normalized variants was annotated using dbNSFP33, and
population frequencies of variants were annotated using vcfanno34 with
1000 Genomes databases. Here we report only MMP20 variants found in
coding regions.
Data availability. Summary statistics of our genome-wide analysis can be
downloaded from the public repository figshare (https://doi.org/10.6084/m9.
figshare.4978145.v3)35. All other remaining data are available within the Article
and Supplementary Files, or available from the authors upon request.
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